Ovarian Function Suppression May Benefit Select Breast Cancer Populations
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Long-Term Data Affirm Enduring Responses With Teclistamab in R/R Multiple Myeloma
Amrita Y. Krishnan, MD, and Binod Dhakal, MD, gave a high-level overview of teclistamab use in the MajesTEC-1 trial.
Expediting Clinical Trial Processes to Advance Brain Cancer Research
Through multidisciplinary collaboration, Yoshie Umemura, MD, and colleagues were able to organize the Gliofocus trial in brain cancer relatively fast.
Exploring GPRC5D as an Important Target for Multiple Myeloma
Experts highlighted the use of GPRC5D therapy in patients with multiple myeloma.
FDA Approves Isatuximab/VRd in Newly Diagnosed Multiple Myeloma
Findings from the phase 3 IMROZ trial support the FDA approval of the combination therapy for newly diagnosed not eligible for ASCT multiple myeloma.
2024 Statistics May Impact Next Decade of Cancer Treatment
Julie M. Vose, MD, MBA, reviews the rising cancer diagnoses that are estimated to impact 2 million people in 2024.
Narmafotinib Earns FDA Fast Track Designation in Advanced Pancreatic Cancer
Data from the interim analysis of the ACCENT trial showed promising signs of efficacy with narmafotinib combination therapy in advanced pancreatic cancer.
Improving Sexual Health After Gynecological Cancer Is a Multifaceted Approach
Pluta Cancer Center clinicians discussed how to improve sexual health outcomes for patients diagnosed with gynecological cancer.
Ruxolitinib Is Under Investigation as JAK Inhibition Strategy for Multiple Myeloma
Ruxolitinib, currently approved as treatment for patients with myelofibrosis and polycythemia vera, is currently undergoing evaluation in myeloma studies.
Amivantamab Plus Chemo Approved by FDA in EGFR-Mutated NSCLC
Results from the MARIPOSA-2 trial led to the approval of amivantamab plus chemotherapy in patients with EGFR-mutated NSCLC.
“Impactful” Data Presentations Raise Hope in the Breast Cancer Field
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Improving Day-to-Day Brain Cancer Care Via Multidisciplinary Collaboration
Yoshie Umemura, MD, discusses how multiple departments can positively impact a patient with brain cancer during their visit to a medical center.
Pelareorep Combo Yields Survival Benefit in HR+/HER2– Breast Cancer
Pelareorep plus paclitaxel improved the overall response rate vs paclitaxel monotherapy among patients in the phase 2 BRACELET-1 study.
Frontline Combination Therapy Intensification May Improve Survival in NSCLC
Higher, durable rates of response to frontline therapy are needed to potentially improve long-term survival among patients with non–small cell lung cancer.
Benmelstobart Combo Improves Outcomes Vs Sunitinib in Advanced RCC
Phase 3 data support benmelstobart/anlotinib as a new potential standard in the frontline treatment of patients with advanced renal cell carcinoma.
Belantamab Mafodotin Combo Regimens Accepted for Review in Japan in R/R MM
A belantamab mafodotin combination regimen has been accepted for review in Japan, based on data from the DREAMM-7 and DREAMM-8 clinical trials.
Azer-Cel Achieves Complete Responses in Relapsed/Refractory DLBCL
Complete responses were observed in a small cohort of patients with DLBCL who have previously received autologous CAR T-cell therapy.
Conference Compendium: The Top 10 Takeaways From ESMO 2024
ESMO 2024 saw a wide range of potentially practice-changing data across multiple oncology disciplines such as the breast cancer and lung cancer fields.
Lenvatinib Combo Yields Substantial Antitumor Activity in Endometrial Cancer
Deep and durable responses were observed with lenvatinib plus pembrolizumab in patients with stage III/IV recurrent endometrial carcinoma.
1-Year Trastuzumab Regimen Yields DFS in ERBB2+ Breast Cancer
DFS was improved with 1-year trastuzumab in patients with ERBB2-positive breast cancer enrolled in the SOLD trial.
FDA Approves Pembrolizumab/Chemo in Unresectable Pleural Mesothelioma
Data from the KEYNOTE-483 trial support the FDA approval of the pembrolizumab-based combination in this pleural mesothelioma population.
Tremelimumab Combo Improves OS Vs Sorafenib in Unresectable Liver Cancer
Treatment with the tremelimumab-based combination also yielded no new serious treatment-related adverse effects in the HIMALAYA study.
Ribociclib Combo Approved in HR+/HER2- Stage II-III Early Breast Cancer
Results from the NATALEE trial of ribociclib/NSAI vs NSAI alone support the approval for patients with HR-positive, HER2-negative early breast cancer.
HER3-DXd Significantly Improves PFS Vs Chemo in Advanced EGFR+ NSCLC
HERTHENA-Lung02 investigators will present further data from the trial at a future medical meeting.
Survival Improves With Atezolizumab Switch Therapy in BRAF+ Melanoma
Phase 2 data also show responses with atezolizumab switch therapy in a population of patients with BRAF V600–positive melanoma.
Neoadjuvant TAR-200 Combo Shows Responses in Muscle-Invasive Bladder Cancer
Data from the SunRISe-4 trial demonstrate the benefit of adding TAR-200 to checkpoint inhibition among patients with muscle-invasive bladder cancer.
Non-Operative Management Does Not Compromise DRFS in pMMR Rectal Cancer
NO-CUT trial data show that DRFS was maintained when non-operative management was used in patients with pMMR locally advanced rectal cancer.
Ribociclib Combo Yields Extended iDFS Benefit in HR+/HER2– Breast Cancer
Data from NATALEE continue to support the addition of ribociclib to adjuvant nonsteroidal aromatase inhibitors in HR-positive, HER2-negative breast cancer.
Breastfeeding Is Feasible Amid Endocrine Therapy Break in HR+ Breast Cancer
Follow-up data show breastfeeding to be feasible among patients with hormone receptor–positive breast cancer during an endocrine therapy break.
Single-Fraction Radiotherapy Improves Pain in Hepatic Cancer
Data from CCTG HE1 also show a numerical improvement an in overall survival with added radiotherapy over best supportive care alone.
